COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

MRI for Assessing Prostate Cancer Response (NA_00067284)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01607008
Recruitment Status : Recruiting
First Posted : May 28, 2012
Last Update Posted : May 12, 2020
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary:

Prostate cancer is one of most common cancers in America, affecting 1 in 6 men. External beam radiation therapy is one of the common methods to treat prostate cancer. Although radiotherapy is effective, side effects to the adjacent normal organs limit the therapeutic ratio. Those side effects are usually associated with the radiation damage of the normal tissue surrounding prostate, e.g. bladder, urethra and rectum etc. Both effectiveness and the side effects of radiation treatment are often accessed after whole course of radiotherapy, which makes the early intervention difficult. The current research project is a feasibility study of utilizing advanced magnetic resonance imaging (MRI) techniques to access radiotherapy treatment response of prostate cancer during and right after radiotherapy.

Many advanced MRI techniques, e.g. spectroscopy (MRS), diffusion-weighted (DWI), dynamic contrast enhanced (DCE) perfusion weighted images, have been used in radiology departments for diagnostic purpose. This research project is to study the feasibility of using advanced MRI sequences to monitor tissue response during and after radiotherapy. The tissue changes revealed from MRI can provide physicians early information on possible tumor recurrence and normal tissue toxicity, therefore, the early intervention may be possible to spare normal tissue and cure the patient. The project is designed to combine several different advanced MRI imaging techniques systematically to study tissue changes during radiotherapy, which has not been seen elsewhere to date.

Another important goal of this research project is to study the feasibility of associating functional MRI with radiation treatment dose distribution. Tissue response during radiation treatment depends on dose. The functional MRI can provide more information than simple anatomic information. Mapping the functional MRI spatially and associating them with 3D dose distribution in radiation treatment planning system is one important step to quantitative assess the relationship between radiation treatment and tissue changes due to the radiation.

Condition or disease Intervention/treatment Phase
Prostate Cancer Other: MRI imaging Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Multiparametric MRI for Assessing Radiotherapy Treatment Response of Prostate Cancer
Actual Study Start Date : November 16, 2012
Estimated Primary Completion Date : May 15, 2022
Estimated Study Completion Date : May 15, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
MRI imaging
Use of MRI imaging in conjunction with standard radiation treatment
Other: MRI imaging

3 total MRI imaging studies:

  1. pre standard radiation treatment
  2. during standard radiation treatment
  3. post standard radiation treatment

Primary Outcome Measures :
  1. MRI use to predict treatment response [ Time Frame: 2 months ]

    To study the feasibility of using magnetic resonance imaging (MRI) to predict treatment response in patients with prostate cancer undergoing radiation therapy. The anatomical, functional, and location changes in tumor or normal tissues during the radiation will be assessed and correlated with MRI data and treatment dose.

    Hypothesis one: Functional or anatomical MRI signal changes during the radiotherapy can be used as predictors to assess treatment response. We anticipate observing dose dependent MRI signal changes during the radiation treatment.

Secondary Outcome Measures :
  1. Evaluating MRI use to predict functional radiation treatment dose distribution [ Time Frame: 2 months ]

    Secondary objective: A secondary objective is evaluating the feasibility of associating functional MRI images with radiation treatment dose distribution. Both tumor control probability and normal tissue complication probability are related to the dose received by patient during the radiotherapy.

    Hypothesis two: With carefull data processing, resampling and registration, the functional MRI data can be imported into radiation treatment planning system. Quantitative analysis to assess tissue changes during radiotherapy and its correlation with radiation dose treatment can be performed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically-confirmed prostate cancer
  • Plan to undergo external radiation treatment of prostate cancer

Exclusion Criteria:

  • Patients who cannot undergo an MRIs
  • Patients who are allergic to gadolinium based contrast agent
  • Patients who have cardiac pacemaker or other electronic or metal implant
  • Patients who have chronic kidney disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01607008

Layout table for location contacts
Contact: Danny Song, M.D. 410-502-5875
Contact: Shirl DiPasquale, R.N. 410-614-1598

Layout table for location information
United States, Maryland
The Sidney Kimmel Comprehsensive Cancer Center at Johns Hopkins Recruiting
Baltimore, Maryland, United States, 21287
Sub-Investigator: Theodore DeWeese, M.D.         
Sub-Investigator: John Wong, Ph.D.         
Sub-Investigator: Yi Ye, M.D.         
Sub-Investigator: Phuoc Tran, M.D.         
Sub-Investigator: Katarzyna Macura, M.D.         
Sub-Investigator: Micahel Jacobs, M.D.         
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Layout table for investigator information
Principal Investigator: Danny Song, M.D. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Layout table for additonal information
Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Identifier: NCT01607008    
Other Study ID Numbers: J11143
NA_00067284 ( Other Identifier: JHM IRB )
First Posted: May 28, 2012    Key Record Dates
Last Update Posted: May 12, 2020
Last Verified: May 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases